Obatoklaks is an experimental drug for the treatment of various types of malignant tumors . It was opened by Gemin X, which was then acquired by Cephalon. [1] Obatoclax is currently in phase II clinical trials for the treatment of leukemia , lymphoma , myelofibrosis and mastocytosis . [2] [3] [4]
| Obatoklaks | |
|---|---|
| General | |
| Chem. formula | C₂₀H₁₉N₃O |
| Classification | |
| Reg. CAS number | |
| Smiles | |
| Inchi | |
| ChemSpider | |
Mechanism of Action
Obatoclax is an inhibitor of the anti- apoptotic BCL-2 family of proteins . [5] By inhibiting the activity of BCL-2, obatoclax induces apoptosis in malignant cells , thereby inhibiting or preventing the growth of a malignant tumor .
Notes
- ↑ Cephalon Announces Definitive Agreement to Acquire Gemin X , March 21, 2011
- ↑ Parikh, Sameer A .; Kantarjian, Hagop; Schimmer, Aaron; Walsh, William; Asatiani, Ekatherine; El-Shami, Khaled; Winton, Elliott; Verstovsek, Srdan. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis (English) // Clinical Lymphoma, Myeloma & Leukemia : journal. - 2010 .-- Vol. 10 , no. 4 . - P. 285-289 . - DOI : 10.3816 / CLML.2010.n.059 .
- ↑ Gemin X Presents New Data on Obatoclax at the American Society of Hematology Meeting , Dec 9, 2008
- ↑ Obatoclax in clinical trials
- ↑ Konopleva, Marina; Watt, Julie; Contractor, Rooha; Tsao, Twee; Harris, David; Estrov, Zeev; Bornmann, William; Kantarjian, Hagop; Viallet, Jean; Samudio, Ismael; Andreeff, Michael. Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax) (Eng.) // Cancer Research : journal. - American Association for Cancer Research 2008. - Vol. 68 , no. 9 . - P. 3413—3420 . - DOI : 10.1158 / 0008-5472.CAN-07-1919 . - PMID 18451169 .